1. Introduction
===============

The proto-oncogene *c-SRC* (*SRC*) is a non-receptor tyrosine kinase, its expression and activity is enhanced in various human cancers and correlates with malignancy progression and development of distant metastasis ([@b1-mco-0-0-02091]). Since there is increasing evidence of its crucial role in tumor progression ([@b4-mco-0-0-02091],[@b5-mco-0-0-02091]) *c-SRC* has emerged as a promising target for anticancer therapy. Consequently, SRC inhibitors have been evaluated in the development of clinical therapies ([@b6-mco-0-0-02091],[@b7-mco-0-0-02091]). However, the exact mechanisms of action of *c-SRC* and the critical respective pathway involved in malignancy are not fully elucidated.

c-SRC is involved in the maintenance of normal cell homeostasis regulating a wide range of cellular events, including cell growth, differentiation, proliferation, survival, adhesion, migration and motility ([@b8-mco-0-0-02091],[@b9-mco-0-0-02091]). In normal cells, the expression levels and activity of c-SRC are strictly regulated by several mechanisms. The kinase activity of c-SRC is controlled by C-terminal SRC kinase (CSK), which phosphorylates a conserved tyrosine residue in the c-SRC carboxy-terminal domain (Tyr530). This is reversed by phosphatases such as protein tyrosine phosphatase 1B (PTP1B), resulting in c-SRC activation. Additionally, activation of growth-factor receptors leads to their association with the c-SRC homology 2 (SH2) domain, which disrupts inhibitory intramolecular interactions to promote c-SRC activation. Other proteins, such as CRK-associated substrate (CAS) and FAK, bind to the c-SRC SH2 and SH3 domains to stimulate c-SRC activation by a similar mechanism. Moreover, c-SRC is also negatively regulated via the ubiquitin-proteasome pathway, which is mediated by E3 ubiquitin-ligase Cbl and Cullin-5 ([@b10-mco-0-0-02091]). Hence, c-SRC is regulated at both transcriptional and post-translational levels by a variety of mechanisms ([@b10-mco-0-0-02091]). The disruption of any of the c-SRC regulatory mechanisms may trigger cancer phenotypes through uncontrolled proliferation, enhanced survival, and invasiveness, in cooperation with other oncogenic signals ([@b2-mco-0-0-02091]). Once activated, as by growth factors or integrins, c-SRC triggers downstream signaling pathways, including the RAS/MAPK, phosphatidylinositol 3-kinase (PI3K)/AKT, and STAT pathways, leading to malignant phenotypic changes ([@b13-mco-0-0-02091]).

2. Discovery of Rous sarcoma virus
==================================

In 1909, at the Rockefeller Institute, Peyton Rous started his studies on a sarcoma that had been developed in the breast muscle of a hen. In his original experiments, Rous managed to transmit the tumor to other birds of the same species, by implanting fragments of the initial tumor. In his subsequent experiments, he developed a short protocol for the induction of tumors in chickens. He used a chicken with sarcoma of breast muscle, removed the mass and broke it up into small chunks of tissue. Subsequently he ground up sarcoma with sand and filtrated it through a fine pore filter. Finally, he injected the filtrate into a young chicken, and observed the growth of sarcomas. He then hypothesized that the tumor-inducing agent should be an oncogenic virus, later becoming known as Rous sarcoma virus (RSV), since this agent was possible to pass through a filter too fine to contain bacteria or chicken cells and was capable of causing cancer with a predictable pattern ([@b14-mco-0-0-02091],[@b15-mco-0-0-02091]). This finding was of great importance as it was the first proof of viral carcinogenesis and thus triggered the discovery of many other types of tumor-inducing viruses in non-human primates such as mice, cats, rabbits ([@b16-mco-0-0-02091]) and later, of the first oncogenic human virus, Epstein Barr in 1964([@b20-mco-0-0-02091]). Additionally, the discovery of this pioneer oncogenic retrovirus (RSV) was the hallmark of the onset of the development of research on the molecular mechanisms of carcinogenesis ([@b21-mco-0-0-02091]).

For almost half a century the research interest was focused on chemical carcinogenesis ([@b22-mco-0-0-02091]). The revival of research regarding oncogenic retroviruses came in 1958 in the Laboratory of Renato Dulbecco. Temin and Rubin developed a quantitative *in vitro* bioassay for the transformation of normal chicken embryonic fibroblasts with RSV. More specifically, in their experiment, they showed that when the virus was introduced to Petri dishes where embryonic fibroblasts where cultured, the RSV(+) cells obtained an evolutionary advantage and were transformed, acquiring cancer morphology under the microscope, i.e., they were less adherent and often rounded up, with increased size and/or number of nucleoli ([@b28-mco-0-0-02091]). In 1966, the Nobel prize was finally awarded to Peyton Rous for his discovery. The next question that arose was whether the transformation of cellular phenotypes was due to the constant influence of the RSV genome. In 1970, an experiment in Berkeley confirmed the above hypothesis. In this experiment, when fibroblasts where cultured with a heat-sensitive mutation of RSV at permissible temperatures (37^°^C) the cells were transformed. When the cultures containing these cells were transferred to an impermissible temperature (41^°^C), the fibroblasts regained their normal morphology and they re-acquired a cancerous morphology when re-exposed to 37^°^C. It was evident that the transforming phenotype was maintained from the ongoing effects of this protein ([@b29-mco-0-0-02091]). The *Src* oncogene of RSV became the prototype for dozens of other transforming genes in oncogenic viruses. Its product was identified by Brugge and Erikson in 1977, as a protein with tyrosine-kinase activity.

3. Cellular origin of retroviral oncogenes
==========================================

In 1961, the RSV was proved to contain an RNA genome ([@b32-mco-0-0-02091]), whose continuous presence was necessary for maintaining cell transformation. However, the mechanism by which the viral RNA genome was incorporated into the infected cells remained undefined. In 1970, the simultaneous research of Temin and Baltimore led to the discovery of reverse transcriptase, an enzyme that catalyzes the transcription of the retroviral RNA into DNA ([@b33-mco-0-0-02091]), and that is also present in RSV. Through reverse transcriptase, the monoclonal RNA of the virus is converted to a double-stranded DNA, and the viral genome is then incorporated into the nuclear DNA via another enzyme, called integrase ([@b34-mco-0-0-02091]). Initially, it was considered that a copy of the *src* transforming gene exists only within infected cells ([@b35-mco-0-0-02091]). In 1974, the laboratory of Michael Bishop and Harold Varmus, taking advantage of the reverse transcriptase, undertook the design of a special gene detector for *src*, in order to understand its properties and origin. To their surprise, they found that the *src* detector could also be hybridized with the genetic material of non-infected cells of chicken and other species (two copies per genome of diploid cells) ([@b35-mco-0-0-02091],[@b37-mco-0-0-02091],[@b38-mco-0-0-02091]). They also observed that the more distant the evolutionary affinity with the chicken, the weaker the degree of hybridization. The data supported the idea that the *src* sequences found in non-infected cells, are actually part of their normal genome (the cellular version of *src*=c-*src*) ([@b35-mco-0-0-02091]). In 1975, the Nobel prize was awarded to Temin and Baltimore, for the discovery of reverse transcriptase ([@b33-mco-0-0-02091],[@b34-mco-0-0-02091]).

From 1976 to 1980 the research focused on the differences between the c-*src* and, the v-*src*, which is located within the RSV genome. The first one exhibited physiological cellular behavior as opposed to the second, which acts as a potent oncogene. The explanation was simple; the *src* gene of RSV was not initially present in the primordial RSV retrovirus. A pre-existing virus (ALV=*src* negative) was detected that caused leukosis in birds and which, through genetic modifications, incorporated sequences from the genome of infected cells (RSV=*src* positive). Subsequent experiments showed that the structure of the RSV genome is closely related to this common infectious agent of birds, called ALV ([@b35-mco-0-0-02091]). Both of them include three genes: *Gag*, *pol* and *env*. The *gag* gene encodes for proteins that take part in the formation of the nucleoprotein nucleus; the *pol* gene encodes for integrase and reverse transcriptase; and the *env* gene determines the glycoprotein precursors. The only difference between the two genomes lies in the ability of the *src* gene to cause cellular transformation ([@b39-mco-0-0-02091],[@b40-mco-0-0-02091]). Thus, for the first time, the concept of proto-oncogene was introduced, implying that a normal gene can be altered by mutation or by a pre-viral insertion, to become an oncogene, thereby contributing to cancer development. Since 1980, retroviruses have been used as probes, to detect the corresponding proto-oncogenes in humans, and researchers have shifted the focus on chemical carcinogenesis ([@b41-mco-0-0-02091]). This second theory confirmed the cellular origin of retroviral oncogenes and additionally contributed to the unravelling of possible mechanisms for proto-oncogene activation, such as amplification, pre-viral insertion, single nucleotide polymorphism and translocation ([@b41-mco-0-0-02091]). In 1989, the Nobel prize was awarded to Bishop and Varmus for the discovery of the cellular origin of retroviral oncogenes ([@b46-mco-0-0-02091],[@b47-mco-0-0-02091]). The most important historic milestones on *Src* research are presented in [Fig. 1](#f1-mco-0-0-02091){ref-type="fig"}.

4. MicroRNAs as the fine tuners of SRC oncogenic signaling
==========================================================

As mentioned above, c-*SRC* is the first reported oncogene and its product is the first non-receptor tyrosine kinase to be identified ([@b48-mco-0-0-02091]). In many human neoplasms, including colorectal, breast, prostate, pancreatic, head and neck, and lung carcinomas, gliomas and melanoma, *SRC* overexpression has already been detected. In fact, its dysregulation could be characterized as an oncogenic signature and as a key factor for tumor progression ([@b3-mco-0-0-02091],[@b5-mco-0-0-02091],[@b49-mco-0-0-02091]). However, the molecular mechanisms underlying c-SRC-mediated tumor progression are not fully understood. Recent studies have highlighted several microRNAs (miRNAs) as key molecules in SRC-mediated tumor progression ([@b50-mco-0-0-02091]). miRNAs are a family of small, endogenous and evolutionarily conserved non-coding RNAs (containing about 22 nucleotides) involved in the regulation of essential cellular and functional processes, including proliferation, differentiation, survival and stress responses. The majority of miRNAs are transcribed from DNA sequences into primary miRNAs (pri-miRNAs) and processed into precursor miRNAs (pre-miRNA), and finally mature miRNAs. Their functionality is bimodal, since they locate complementary mRNAs and either regulate protein translation or induce degradation of the target mRNA ([@b51-mco-0-0-02091]). Hence, miRNAs act either as oncogenes or tumor suppressors and are important regulators of gene expression at the post-transcriptional level ([@b52-mco-0-0-02091]). In subsequent experiments, microarray profiling revealed that c-SRC regulates a set of miRNAs, which act as tumor suppressors, when their expression is downregulated. Generally, miRNAs are commonly silenced in human cancers by mutation, methylation, loss of heterogeneity or by other post-transcriptional modifications ([@b53-mco-0-0-02091]). Studies on the function of these miRNAs uncovered miRNA-mediated c-SRC oncogenic signaling and crosstalk between *Src* and other oncogenic signaling pathways, such as the focal adhesion-mediated pathway and the mammalian target of rapamycin, mTOR ([@b50-mco-0-0-02091]).

Recently, the mechanisms underlying SRC-mediated activation of mTOR signaling, a major downstream effector of the PI3K pathway, were found to be regulated by miRNA expression in various cancer types ([@b54-mco-0-0-02091],[@b55-mco-0-0-02091]). More precisely, functional analysis showed that transcription of miR-99a, which is often downregulated in various human cancers, and is regulated by SRC-related oncogenic pathways, like the epidermal growth factor receptor (EGFR) pathway. It was demonstrated that mir-99a targets mTOR and fibroblast growth factor receptor 3 (FGFR3), both of which are strongly related with human cancers ([@b56-mco-0-0-02091],[@b57-mco-0-0-02091]). In conclusion, this study indicated that miR-99a is the missing link between SRC and mTOR, which have both been correlated with human cancer. Furthermore, miRNA-mediated mTOR regulation has also been shown in studies of miR-100 and miR-199-3p ([@b58-mco-0-0-02091],[@b59-mco-0-0-02091]). Further studies suggested that miRNAs also regulate focal adhesion and activation of downstream effectors in SRC-activated cancer cells. More specifically, integrin-linked kinase (ILK) is targeted by miR-542-3p, a downregulated miRNA in SRC-transformed cells ([@b60-mco-0-0-02091]). Apart from the fact that downregulation of miR-542-3p corresponds with upregulation of c-SRC and ILK, there is also a correlation between ILK upregulation and c-SRC activation in human colon cancer tissues. Furthermore, it was found that miR-542-3p-mediated ILK downregulation induces inactivation of c-SRC and FAK in human colon cancer cells (feedback loop).

Last but not least, miRNA mediates regulation of *SRC* expression itself, and this could also be a logical explanation for the resistance that is observed when SRC-targeting drugs are used. In detail, miR-23b functions as a tumor suppressor and as a mediator of metastasis in different cell lines ([@b64-mco-0-0-02091]). miR-27b, which targets paxillin, a platform for adaptor proteins and a critical component of the focal adhesion complex, is under the control of the PI3K pathway ([@b65-mco-0-0-02091]). Taking into consideration that both of them are downregulated in human castration-resistant prostate cancers ([@b69-mco-0-0-02091]), c-SRC could be regulated by the miR-23b/27b 24-1 gene cluster via a dual mechanism: Regulation of c-SRC kinase activity via either miR-27b or miR-23b mediated regulation of paxillin. As a result, upregulation of c-*SRC* expression may amplify the positive-feedback loop mediated by the miR-23b/27b 24-2 gene cluster thus, inducing tumor progression mediated by c-SRC activity ([@b50-mco-0-0-02091]).

5. miRNA-mediated SRC oncogenic signaling in selected cancer types
==================================================================

As many miRNAs are down-regulated in human cancers through various genetic and epigenetic alterations, such as methylation and loss of heterogeneity, research was focused on the role of down-regulated miRNAs in c-SRC transformation ([@b53-mco-0-0-02091]). Subsequent experiments highlighted the key role of miR-137 in the development of SRC-mediated human colon cancer ([@b70-mco-0-0-02091]). To elucidate the role of miR-137 and its correlation with SRC signaling, the HCT116 cell line, anti-sense miRNAs and also dasatinib (a specific SRC kinase inhibitor) were used. It was finally concluded that miR-137 is down-regulated in the early stages of cancer progression ([@b70-mco-0-0-02091]). In another experiment, the role of miR-129-1-3p in human colon cancer was evaluated by assessing miR-129-1-3p expression in 10 pairs of primary colon tumors and adjacent non-cancerous tissues using qRT-PCR and western blot analysis to examine the activity of SFK (SRC pY418). It was clarified that miR-129-1-3p was markedly downregulated and SFK activity was greatly upregulated in colon cancer tissues ([@b71-mco-0-0-02091]). Additional studies demonstrated that certain miRNAs induce SRC oncogenic signaling by targeting SRCIN1, a specific SRC kinase signaling inhibitor. For example, miR-665 suppresses SRCIN1 expression, which normally acts as a negative regulator of MAPK/ERK signaling in ovarian cancer cells ([@b72-mco-0-0-02091]). In ovarian cancer, sustained activation of MAPK/ERK signaling is associated with strong cell proliferation and metastatic potential ([@b73-mco-0-0-02091]). The western blotting results showed that inhibition of miR-665 increased SRCIN1, at both the mRNA and protein level, and inactivated MAPK/ERK pathway in ovarian cancer ([@b74-mco-0-0-02091]). Similar findings were reported in the case of miR-150. It was observed that miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signaling inhibitor 1 (SRCIN1), therefore acting as an oncogene ([@b75-mco-0-0-02091]). Subsequent studies examined the role of miR-17-5p in the evolution of osteosarcoma and revealed a component of the miR-17-5p/SRCIN1/EMT signaling pathway. Furthermore, classic EMT markers such as N-cadherin, E-cadherin and Snail were quantified by western blot analysis. Finally, it was proven that SRCIN1 is a direct target of miR-17-5p and silencing of this miRNA could change the expression of EMT markers and arrest cell growth ([@b76-mco-0-0-02091]). SRCIN1 was found to be downregulated in breast cancer in previous studies ([@b77-mco-0-0-02091]). Moreover, miR-374a was shown to induce cell proliferation, invasion and migration of gastric cancer cell via binding to SRCIN1([@b78-mco-0-0-02091]). It was also found to be involved in pancreatic cancer through the axis miR-374a/SRCIN1/EMT ([@b79-mco-0-0-02091]). Finally, a recent study focused on the identification of miR-373 levels in metastatic neuroblastoma samples and its interaction with SRCIN1([@b80-mco-0-0-02091]).

In conclusion, it becomes evident that miRNA dysfunction is involved in various human cancers and miRNAs can function as both oncogenes and tumor suppressors ([@b81-mco-0-0-02091],[@b82-mco-0-0-02091]). Due to their implication in the regulation of sustained cell growth signaling, miRNAs are considered as potential biomarkers and therapeutic targets for cancer treatment ([@b83-mco-0-0-02091]).

6. Exosomes as the fine tuners of oncogenic signaling
=====================================================

As mentioned above, *SRC* functions as a molecular signaling switch and plays a central role in the regulation of cell proliferation, differentiation, adhesion, and migration in normal cells ([@b8-mco-0-0-02091]), and is commonly upregulated in various human cancer cells. The activation of *src* is strictly regulated by several molecular mechanisms. For example, the kinase activity of SRC is negatively regulated by the phosphorylation of a regulatory tyrosine at its c-terminal tail, catalyzed by CSK ([@b84-mco-0-0-02091],[@b85-mco-0-0-02091]). On the other hand, SRC is positively regulated through several extracellular signals, such as growth factors and extracellular matrices, which lead to the interaction with certain adaptor proteins, including FAK and Cas ([@b49-mco-0-0-02091],[@b86-mco-0-0-02091]), and consequently to the activation of downstream signaling pathways. Furthermore, cellular localization of SRC, determines its activity. Inactive SRC is located to the perinuclear region, and once activated, it is translocated to the plasma membrane, under the control of members of the Rho family ([@b87-mco-0-0-02091]).

Recent studies have shown that activated SRC is downregulated through degradation by either lysosomes or proteasomes, with the functional difference between them remaining unclear ([@b10-mco-0-0-02091],[@b88-mco-0-0-02091]). More precisely, the E3 ubiquitin ligase Cbl mediates the ubiquitination of SRC and induces its degradation via the ubiquitin-proteasome pathway ([@b89-mco-0-0-02091],[@b90-mco-0-0-02091]). In a recent study, ubiquitination of activated SRC at Lys429 was demonstrated to promote its secretion via small extracellular vesicles (sEVs) ([@b91-mco-0-0-02091]). In this experiment, MDCK cells expressing a modified *SRC* that can be activated by hydroxytamoxifen were used in order to mimic SRC upregulated cancer cells. When proteasome inhibition (MG132) was performed, no accumulation of ubiquitinated SRC was noted, suggesting that ubiquitination of SRC preferentially promotes its secretion via sEVs to decrease the levels of activated SRC in these cells. It was also identified that Lys 429 is a critical ubiquitination site required for sEV-mediated secretion. In an attempt to determine how the mutation at Lys429 on SRC (R429) affects the cell, it was observed that it caused resistance to ubiquitination and decreased its secretion via sEVs. Additionally, since the cbl ablation caused a less potent suppression of the sEV secretion, it was hypothesized that other E3 ligases might also be required. In addition, activation of R429 mutant enhanced SRC-induced invasive phenotypes, supporting the hypothesis of a stronger activation of FAK at the early stages ([@b86-mco-0-0-02091],[@b91-mco-0-0-02091]). These findings have shed light on this missing link between SRC ubiquitination and sEV secretion, and suggest a tumor suppressive role for the secretion of SRC via sEVs. The fact that SRC is detected in exosomes from various cancer cells, such as colorectal ([@b92-mco-0-0-02091]), prostate ([@b93-mco-0-0-02091]), and breast ([@b94-mco-0-0-02091]) cancer cells, indicates that secretion of SRC via exosomes may be a common mechanism used to regulate SRC in a wide array of cell types and seems to constitute a novel promising therapeutic target ([@b95-mco-0-0-02091]).

7. SRC inhibitors as anticancer agents in clinical trials
=========================================================

The role of *SRC* in oncogenesis has prompted the detection of other members of the SRC family of protein kinases and the search for anticancer therapies. To this end, most of the FDA-approved inhibitors of related protein kinases are directed toward neoplastic diseases. However, since SRC is not a primary driver of tumorigenesis, but rather a participant in pathways of cell division, invasion, migration and survival, administration of existing inhibitors of SRC as a monotherapy has not been proved efficient in cancer treatment ([@b96-mco-0-0-02091]). Moreover, there are currently no available prognostic biomarkers related to SRC activity that could be used for patient selection in clinical trials.

Currently, four oral SRC/multi-kinase inhibitors have been approved by the FDA for the treatment of various malignancies. Bosutinib, a BCR-Abl, SRC, Lyn, Hck, Kit, and PDGFR inhibitor approved for the treatment of Philadelphia-positive chronic myeloid leukemia (Ph^+^CML) and acute lymphoblastic leukemia (ALL), is currently evaluated in clinical trials for the treatment of breast cancer, glioblastoma and other solid tumors ([@b97-mco-0-0-02091]). Dasatinib, an inhibitor of BCR-Abl, SRC, Lck, Fyn, Yes, PDGFR, and other kinases, approved for the treatment of CML is currently evaluated in clinical trials against various solid tumors ([@b100-mco-0-0-02091]). This inhibitor is also evaluated in combination with insulin-like growth factor 1 Receptor (IGF-1R) antibody AMG479 against embryonal or alveolar rhabdomyosarcoma. Ponatinib, an inhibitor of BCR-Abl, PDGFR, VEGFR, members of the SRC family and other kinases, approved for the treatment of CML and ALL is currently evaluated in clinical trials against several leukemias ([@b101-mco-0-0-02091]). Vandetanib is an inhibitor of EGFR, VEGFR, RET, members of the SRC family and other kinases, approved for the treatment of medullary thyroid carcinoma and is currently evaluated in clinical trials against numerous solid tumors ([@b102-mco-0-0-02091]). Saracatinib (AZD0530) an SRC and BCR-Abl inhibitor is currently evaluated in clinical trials against colorectal, gastric, ovarian, small and non-small cell lung cancers and against metastatic osteosarcoma in the lung ([@b105-mco-0-0-02091]). A related drug (AZD0424) alone or in combination with other agents is in Phase I clinical trials against various types of solid tumors. KX2-391 is another orally administered small molecule SRC kinase inhibitor with potential antineoplastic activity. Interestingly, instead of binding to the ATP-binding site, like other SRC inhibitors, KX2-391 specifically binds to the peptide substrate binding site of SRC kinase; in this way, kinase activity is eliminated, potentially resulting in the inhibition of primary tumor growth and the suppression of metastasis. This inhibitor is being evaluated in clinical trials against multiple cancer types, either alone or in combination with paclitaxel ([@b108-mco-0-0-02091]).

At present, there is a critical number of clinical trials that investigate the therapeutic value of putative specific SRC or SRC-related inhibitors as anti-cancer agents, alone or in combination with other agents ([Table I](#tI-mco-0-0-02091){ref-type="table"}) ([@b108-mco-0-0-02091]). The clinical efficacy of these agents against the above-mentioned cancer types remains to be established.

8. Conclusion
=============

The discovery of the *Src* gene was the trigger for the emergence of other oncogenes, as well as the understanding of the genetic basis of cancer. Therefore, different molecular mechanisms are involved in tumor progression, differentiation and migration. Despite the fact that the *src* gene is now well studied, the molecular pathways mediating cancer progression have not yet been clarified. The contribution of miRNAs and exosomes in the acquisition of malignant phenotype may contribute an emerging therapeutic strategy of combinational therapies with dual pathway inhibition, although further studies are needed. Finally, both exosomes and miRNAs could be useful diagnostic, prognostic and predictive biomarkers in SRC-induced carcinogenesis, thus contributing to a more rational and effective classification and treatment of these patients.
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Combinatorial treatments of specific SRC or SRC-related inhibitors and other anti-cancer agents in clinical trials (Only studies with published results are shown).

  SRC inhibitor           Combinatorial treatment   Additional molecular target(s)      Cancer type                                                                                   Clinical phase   [ClinicalTrials.gov](ClinicalTrials.gov) Identifier   Results/Major side effects
  ----------------------- ------------------------- ----------------------------------- --------------------------------------------------------------------------------------------- ---------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dasatinib               Afatinib                  EGFR                                NSCLC                                                                                         Phase I          NCT01999985([@b109-mco-0-0-02091])                    The MTD of Afatinib in combination with Dasatinib was set to 40 and 140 mg, respectively. All subjects showed an objective response rate within 6 months. PFS rate in participants with acquired EGFR resistance was measured to 5.5 (2.6 to 8.5) months. Mainly mild adverse effects including anemia, diarrhea, nausea, vomiting, cough and fatigue.
                          Trastuzumab, Paclitaxel   HER2, Chemotherapeutic treatment    Metastatic breast cancer                                                                      Phase I/II       NCT01306942([@b110-mco-0-0-02091])                    ORR was 79.3% (95% CI 60.3-92), clinical benefit rate 82.8% (95% CI 64.2-94.2). Median time to progression 23.9 months, median PFS 23.9 months. No grade 4 toxicity was seen. Grade 3 toxicities included: Ejection fraction decrease, neutropenia, hyponatremia, fatigue and sensory neuropathy and one left ventricular systolic dysfunction. Phosphorylated (p)-SRC was reduced in peripheral blood mononuclear cells. Phosphorylated SRC, ERK and AKT were also reduced in epidermal keratinocytes.
                          Ixabepilone               Chemotherapeutic treatment          Metastatic breast cancer                                                                      Phase I/II       NCT00924352([@b111-mco-0-0-02091])                    The MTD of dasatinib (taken daily, continuously) when given in combination with ixabepilone (administered on Days 1, 8, and 15 of a 28-day cycle) was determined at 100 mg. Respectively, the MTD of ixabepilone was 20 mg/m^2^. The PFS of the Combination of Dasatinib and Ixabepilone (Phase II) was 6.01 (2.92 to 8.08) months. 19.64% faced serious adverse effects, while many patients had diarrhea, neutropenia, anemia, nausea and fatigue.
                          Docetaxel                 Chemotherapeutic treatment          Metastatic Hormone Refractory Prostate Cancer                                                 Phase I/II       NCT00439270([@b112-mco-0-0-02091])                    Thirteen of 46 patients (28%) had a grade 3-4 toxicity. Durable 50% PSA declines occurred in 26 of 46 patients (57%). 60% had a partial response. 30% had disappearance of a lesion on bone scan. In bone marker assessments, 33 of 38 (87%) and 26 of 34 (76%) had decreases in urinary N-telopeptide or bone-specific alkaline phosphatase levels, respectively. 61% received single-agent dasatinib after docetaxel discontinuation and had stabilization of disease for an additional 1 to 12 months.
                          Erlotinib                 EGFR                                NSCLC                                                                                         Phase I/II       NCT00826449([@b113-mco-0-0-02091])                    MTD was 150 mg of erlotinib and 70 mg of dasatinib daily based on 12 patients treated in the phase I portion. The 35 NSCLC patients treated in phase II had an overall disease control rate of 59% at 6 weeks. Five patients (15%) had partial responses; all had activating EGFR mutations. Median PFS was 3.3 months.
  Bosutinib               Exemestane                Hormonal antineoplastic treatment   Metastatic hormone receptor-positive/HER2-negative breast cancer (in post-menopausal women)   Phase II         NCT00793546([@b114-mco-0-0-02091])                    93% of the patients experienced treatment-related adverse effects, including diarrhea and hepatotoxicity; 10% faced serious treatment-related adverse effects. One patient (300 mg/day) achieved confirmed partial response; three (400 mg/day, n=2; 300 mg/day, n=1) maintained stable disease for \>24 weeks; a best response of progressive disease occurred in 36% of the patients. Median PFS was 12.3 weeks (80% confidence interval: 11.0-15.6).
                          Letrozole                 Hormonal antineoplastic treatment   Breast cancer (in post-menopausal women)                                                      Phase II         NCT00880009([@b115-mco-0-0-02091])                    69% of the subjects experienced treatment-related adverse effects, most commonly diarrhea. Treatment-related hepatotoxicity occurred in 38%. One patient achieved confirmed partial response; one had stable disease for \>24 weeks.
                          Capecitabine              Chemotherapeutic treatment          Advanced solid tumors                                                                         Phase I/II       NCT00959946([@b116-mco-0-0-02091])                    No dose-limiting toxicities observed. 6% experienced dose limiting toxicities. Most common treatment-related adverse events were diarrhea, nausea, vomiting, palmar-plantar erythrodysesthesia (PPE), fatigue. Best overall confirmed partial response or stable disease \>24 weeks (all tumor types) was observed in 6 and 13% of patients.
                          Imatinib                  BCR-ABL                             Chronic Myelogenous Leukemia                                                                  Phase III        NCT02130557([@b117-mco-0-0-02091])                    The MMR rate at 12 months was significantly higher with bosutinib vs. imatinib (47.2% vs. 36.9%, respectively; P=.02), as was complete cytogenetic response (CCyR) rate by 12 months (77.2% vs. 66.4%, respectively; P=.0075). Cumulative incidence was favorable with bosutinib with earlier response times. 1.6% receiving bosutinib and 2.5% receiving imatinib experienced disease progression to accelerated/blast phase. 22.0% of patients receiving bosutinib and 26.8% of patients receiving imatinib discontinued treatment, most commonly for drug-related toxicity (12.7 and 8.7%, respectively). Cardiac and vascular toxicities were uncommon.
  Saracatinib (AZD0530)   Carboplatin, Paclitaxel   Chemotherapeutic treatment          Advanced ovarian cancer                                                                       Phase II         NCT00610714([@b118-mco-0-0-02091])                    ORR for triple combination patients was 53,4%. PFS for triple combination was 8.28 (0 to 11.04) months, over 7.79 (0.72 to 12.12) months for double combination without Saracatinib. Serious adverse effects were recorded in 43.81% of the patients, including mainly febrile neutropenia. Non-serious adverse effects were observed in 97.14% of the subjects.
                          Paclitaxel                Chemotherapeutic treatment          Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer                              Phase II/III     NCT01196741([@b119-mco-0-0-02091])                    The 6-month PFS rate was 29% (Pxl + S) vs. 34% (wPxl + P) (P=0.582). Median PFS was 4.7 vs. 5.3 months (hazard ratio 1.00, 95% confidence interval 0.65-1.54; P=0.99). Rate Response (complete + partial) was 29% (wPxl + S) vs. 43% (wPxl + P), P-value=0.158. Grade 3/4 adverse events were 36% vs. 31% (P=0.624); the most frequent G3/4 toxicities were vomiting, abdominal pain and diarrhea. Febrile neutropenia was more common in the saracatinib arm (4.3%) than placebo (0%). Response, PFS and Overall survival were all significantly (P\<0.05) better in patients with taxane interval ≥6 months/no prior taxane (n=85) than those \<6 months (n=22), regardless of randomisation.
